OTCMKTS:PPTDF PeptiDream (PPTDF) Stock Price, News & Analysis $5.98 -0.62 (-9.39%) As of 06/9/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About PeptiDream Stock (OTCMKTS:PPTDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PeptiDream alerts:Sign Up Key Stats Today's Range$5.98▼$6.6050-Day Range$5.98▼$8.2652-Week Range$5.98▼$13.53Volume300 shsAverage Volume639 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PeptiDream Inc. (OTCMKTS:PPTDF) is a Tokyo-based biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics. Since its founding in 2006, the company has built a proprietary Peptide Discovery Platform System (PDPS) that combines encoded peptide libraries with high-throughput screening to identify new macrocyclic and constrained peptides. These compounds are designed to bind with high specificity and affinity to challenging targets, including protein–protein interactions that are often undruggable by conventional small molecules. The company’s core business model centers on collaborating with global pharmaceutical and biotechnology partners, granting access to its PDPS for early‐stage drug discovery programs. PeptiDream has established alliances with leading industry players across North America, Europe and Asia, leveraging its platform to generate candidate peptides against a wide range of therapeutic targets, from oncology to metabolic and infectious diseases. In addition to partnership revenues, PeptiDream maintains its own internal pipeline of preclinical assets that utilize its platform’s unique capabilities. Headquartered in Tokyo, PeptiDream operates research facilities in Japan, with business development teams engaged worldwide to support collaborative research and licensing agreements. The company is led by Chief Executive Officer Nobuji Tsukada, whose experience in pharmaceutical R&D and strategic partnerships has guided PeptiDream’s growth in the peptide therapeutics arena. Under his leadership, PeptiDream continues to refine its technology platform and expand its partner network, aiming to bring novel peptide drugs into clinical development and ultimately to patients in need.AI Generated. May Contain Errors. Read More Receive PPTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PeptiDream and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPTDF Stock News HeadlinesPeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration PartnerApril 20, 2026 | businesswire.comPeptiDream Inc. (PPTDF) Q4 2025 Earnings Call TranscriptFebruary 16, 2026 | seekingalpha.comUncle Sam now owns 9.9% of IntelOn August 22, 2025, the U.S. government became one of Intel's largest shareholders - converting CHIPS Act grants into a 9.9% equity stake worth 8.9 billion dollars at 20.47 per share. Weeks earlier, the DoD took a 15% stake in rare-earth miner MP Materials, and the DOE followed with a 5% stake in Lithium Americas alongside a 2.23 billion dollar loan. Federal equity ownership in semiconductors, rare earths, and lithium - at this scale - hasn't happened since World War II. Porter Stansberry says the rules of investing are changing, and the stocks positioned to win this realignment aren't the ones the financial press is covering. | Porter & Company (Ad)Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in JapanFebruary 4, 2026 | globenewswire.comSee More Headlines PPTDF Stock Analysis - Frequently Asked Questions How have PPTDF shares performed this year? PeptiDream's stock was trading at $12.48 at the beginning of the year. Since then, PPTDF stock has decreased by 52.1% and is now trading at $5.98. How do I buy shares of PeptiDream? Shares of PPTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/09/2026Next Earnings (Estimated)8/12/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PPTDF CIKN/A Webwww.peptidream.com Phone81-4-4270-1300FaxN/AEmployees603Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:PPTDF) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThis IPO Could Make SpaceX Look Small (Read before June 16)A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PeptiDream Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PeptiDream With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.